GlassScriptPhysician profile
Lillian M Nicks
NPI 1558641670
$6,070.11
in general payments reported to CMS, 2019-2025
35 companies · $1,971 in 2025
The $1,971 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $669 · 2023: $1,114 · 2024: $1,678 · 2025: $1,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219 · Long Term Medical Supply Or Device Loan: $2,082 · Consulting Fee: $265 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.24 |
| Long Term Medical Supply Or Device Loan | $2,081.77 |
| Consulting Fee | $265.00 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,114.57 | 2023-2025 | |
| Incyte Corporation | $551.34 | 2021-2025 | Niktimvo, Jakafi, Pemazyre |
| Glaxosmithkline, LLC. | $499.33 | 2021-2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $384.15 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Janssen Scientific Affairs, LLC | $183.85 | 2024-2025 | Rybrevant, Talvey |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Acrotech Biopharma INC. | $160.53 | 2023-2024 | Beleodaq |
| Kite Pharma, INC. | $159.54 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $157.53 | 2021-2023 | Tazverik |
| Bayer Healthcare Pharmaceuticals INC. | $146.68 | 2022 | |
| Janssen Biotech, INC. | $138.99 | 2022-2025 | Carvykti, Rybrevant |
| Mallinckrodt Hospital Products INC. | $136.48 | 2023 | Uvadex |
| Seagen INC. | $130.01 | 2021-2023 | Padcev |
| Astellas Pharma Global Development | $126.68 | 2024-2025 | Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $124.14 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $119.70 | 2025 | |
| Amgen INC. | $114.14 | 2022-2023 | Kyprolis |
| Jazz Pharmaceuticals INC. | $106.42 | 2022-2024 | |
| Genzyme Corporation | $93.41 | 2022-2023 | |
| Lilly USA, LLC | $71.26 | 2024 | Verzenio |
| Gilead Sciences, INC. | $67.06 | 2022-2023 | Trodelvy |
| Taiho Oncology, INC. | $52.39 | 2022-2023 | |
| Celgene Corporation | $35.18 | 2023 | Pomalyst |
| Novocure INC. | $25.00 | 2022 | |
| Servier Pharmaceuticals LLC | $24.75 | 2023 | |
| Eisai INC. | $23.76 | 2023 | |
| Abbvie INC. | $21.45 | 2023 | |
| Adaptive Biotechnologies Corporation | $21.10 | 2022 | |
| Daiichi Sankyo INC. | $17.94 | 2022 | |
| G1 Therapeutics, INC. | $16.99 | 2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $16.41 | 2023 | Fotivda |
| Beigene USA, INC. | $16.20 | 2023 | Brukinsa |
| Pfizer INC. | $13.16 | 2021 | |
| Exelixis INC. | $12.62 | 2022 | |
| Rigel Pharmaceuticals, INC. | $12.35 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Nicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.